@laurakulik1 @docamitgs @AnjanaPillaiMD @AkshataMoghe @DJPinato @NDP1001 @AndrewMMoon @riadsalemIR @HPB_Txp_Surg @Zhu_Lab @ShaalanBeg Most data (outside of the recent Sinai series) is in the post transplant setting with high rates of rejection with ICIs -
Noha Abdel-Wahab @NohaMDAnderson , First Author – “#Checkpoint inhibitor therapy for cancer in solid organ #transplantation recipients: an institutional experience and a systematic review of the literature” https://t.co/EAGna9ZnmD @MDAndersonNews https:/
@sapisochin @MathurAmitK @nicole_rich8 @SultanMahmoodMD @LizzieAbyMD @GiJournal @HEP_Journal @AniKardashianMD @elizabeth_verna @theliversurgeon @UNOSNews @jmarrero6713 @docamitgs @ibsimpact Exciting times for HCC with IO combos, but agree completely with @
RT @iskander: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systemat…
It makes absolutely perfect sense and yet the numbers are stunning.
RT @iskander: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systemat…
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature: https://t.co/ffGTLHXxrf
RT @UmutSelametMD: Ala Abudayyeh @MDAndersonNews https://t.co/adxZXu4KVG
RT @sitcancer: #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experien…
RT @sitcancer: #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experien…
RT @sitcancer: #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experien…
#JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature https://t.co/ZRJYt5LCaS https://t.co/2CuH83SCqq
RT @sitcancer: #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experien…
RT @sitcancer: #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experien…
RT @sitcancer: #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experien…
RT @sitcancer: #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experien…
#JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature https://t.co/ZRJYt5LCaS https://t.co/Q2PZs9KSty
RT @Immunotx_papers: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a s…
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. https://t.co/b3DdRwShiE
@RoxanaDaneshjou @JAMADerm If the other link doesn’t work... https://t.co/kRCRre6ugE 4/
RT @sitcancer: New #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional expe…
RT @sitcancer: New #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional expe…
New #JITC Research: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature https://t.co/ZRJYt5LCaS https://t.co/AVvog3KaG4